HK1030625A1 - Methods and compositions for immunomodulation - Google Patents

Methods and compositions for immunomodulation

Info

Publication number
HK1030625A1
HK1030625A1 HK01101094A HK01101094A HK1030625A1 HK 1030625 A1 HK1030625 A1 HK 1030625A1 HK 01101094 A HK01101094 A HK 01101094A HK 01101094 A HK01101094 A HK 01101094A HK 1030625 A1 HK1030625 A1 HK 1030625A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
protein
useful
disclosed
Prior art date
Application number
HK01101094A
Other languages
English (en)
Inventor
Reginald M Gorczynski
David A Clark
Original Assignee
Transplantation Technologies I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22058127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1030625(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transplantation Technologies I filed Critical Transplantation Technologies I
Publication of HK1030625A1 publication Critical patent/HK1030625A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
HK01101094A 1997-11-07 2001-02-15 Methods and compositions for immunomodulation HK1030625A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6476497P 1997-11-07 1997-11-07
PCT/CA1998/001038 WO1999024565A1 (en) 1997-11-07 1998-11-06 Methods and compositions for immunomodulation

Publications (1)

Publication Number Publication Date
HK1030625A1 true HK1030625A1 (en) 2001-05-11

Family

ID=22058127

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01101094A HK1030625A1 (en) 1997-11-07 2001-02-15 Methods and compositions for immunomodulation

Country Status (13)

Country Link
US (6) US6338851B1 (xx)
EP (1) EP1032662B1 (xx)
JP (2) JP4584447B2 (xx)
AT (1) ATE319825T1 (xx)
AU (1) AU748587B2 (xx)
CA (1) CA2308765C (xx)
CY (1) CY1105364T1 (xx)
DE (1) DE69833779T2 (xx)
DK (1) DK1032662T3 (xx)
ES (1) ES2260852T3 (xx)
HK (1) HK1030625A1 (xx)
PT (1) PT1032662E (xx)
WO (1) WO1999024565A1 (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032662B1 (en) 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
AU6615500A (en) * 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
AU4215901A (en) 2000-03-17 2001-09-24 Reginald M Gorczynski Methods and compositions for immunoregulation
ES2292587T3 (es) * 2000-04-22 2008-03-16 Pharmedartis Gmbh Agentes apoptoticos.
WO2002011762A2 (en) * 2000-08-03 2002-02-14 Gorczynski Reginald M Methods and compositions for modulating tumor growth
AUPR069500A0 (en) * 2000-10-11 2000-11-09 Coster, Douglas John Tissue modification
JP2004513660A (ja) * 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2002246632B2 (en) 2000-12-08 2007-04-05 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6906237B2 (en) * 2001-02-27 2005-06-14 G. Scott Herron Vivo assay for anti angiogenic compounds
US7285631B2 (en) 2001-08-10 2007-10-23 Serono Genetics Institute S.A. Human cDNAs and proteins and uses thereof
EP1439857B1 (en) * 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
US7196243B2 (en) 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
WO2004060295A2 (en) * 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
US7741038B2 (en) 2005-03-14 2010-06-22 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
GB0506721D0 (en) * 2005-04-01 2005-05-11 Univ Glasgow Soluble immunoregulatory factor
NZ569903A (en) 2006-01-12 2012-07-27 Alexion Pharma Inc Antibodies to OX-2/CD200 and uses thereof
WO2008085963A1 (en) * 2007-01-05 2008-07-17 University Of Florida Research Foundation, Inc. Materials and methods for the detection, prevention and treatment of autoimmune disease
AU2008279618B2 (en) 2007-07-25 2014-05-22 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
JP2010534243A (ja) 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２００に対する抗体および免疫応答への使用
WO2010083121A1 (en) 2009-01-15 2010-07-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarker panel for diagnosis and prediction of graft rejection
US9290813B2 (en) 2009-12-02 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
JP2013519682A (ja) 2010-02-11 2013-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を使用する治療方法
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
WO2012125182A1 (en) 2011-03-11 2012-09-20 Synageva Biopharma Corp Npp1 fusion proteins
EP2550371A4 (en) 2010-03-25 2013-11-20 Univ Leland Stanford Junior PROTEIN AND GENE BIOMARKERS FOR EXTRACTING ORGAN TRANSPLANTS
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
EP3967755B1 (en) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
US10888609B2 (en) 2015-11-03 2021-01-12 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
WO2017218786A1 (en) 2016-06-16 2017-12-21 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
TW201803905A (zh) 2016-06-20 2018-02-01 克馬伯有限公司 用於免疫腫瘤學之多重專一性抗體
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
JP7511469B2 (ja) 2017-09-27 2024-07-05 イノザイム ファーマ， インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
WO2019084682A1 (en) 2017-10-30 2019-05-09 Mcmaster University Methods for the diagnosis and treatment of endometriosis
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606217B2 (en) * 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
GB9505653D0 (en) * 1995-03-21 1995-05-10 Shober Wharton Method of pest control
WO1997021450A1 (en) * 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Ox-2 costimulatory molecule
CA2246352C (en) * 1996-03-20 2011-11-08 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
EP1032662B1 (en) 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
AU4215901A (en) 2000-03-17 2001-09-24 Reginald M Gorczynski Methods and compositions for immunoregulation
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
CA2448668A1 (en) 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation of cd200 receptors
US7196243B2 (en) * 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery

Also Published As

Publication number Publication date
CA2308765C (en) 2010-10-12
JP2010155846A (ja) 2010-07-15
DE69833779T2 (de) 2006-11-30
US20110206668A1 (en) 2011-08-25
WO1999024565A1 (en) 1999-05-20
JP2001522867A (ja) 2001-11-20
EP1032662B1 (en) 2006-03-08
PT1032662E (pt) 2006-07-31
JP4584447B2 (ja) 2010-11-24
ES2260852T3 (es) 2006-11-01
US20090232825A1 (en) 2009-09-17
US20020086011A1 (en) 2002-07-04
CY1105364T1 (el) 2010-03-03
US6984625B2 (en) 2006-01-10
ATE319825T1 (de) 2006-03-15
CA2308765A1 (en) 1999-05-20
AU748587B2 (en) 2002-06-06
EP1032662A1 (en) 2000-09-06
US6749854B2 (en) 2004-06-15
DE69833779D1 (de) 2006-05-04
US20020151485A1 (en) 2002-10-17
US6652858B2 (en) 2003-11-25
US7902151B2 (en) 2011-03-08
US6338851B1 (en) 2002-01-15
AU1017399A (en) 1999-05-31
US20020103151A1 (en) 2002-08-01
DK1032662T3 (da) 2006-07-03

Similar Documents

Publication Publication Date Title
HK1030625A1 (en) Methods and compositions for immunomodulation
PL328858A1 (en) Immunogenous peptides
EP0687183A4 (en) SYNERGISTIC COMPOSITION OF A CD4-BASED PROTEIN AND ANTIBODY AGAINST HIV-1, AND METHODS OF USE
GB2288732B (en) Pharmaceutical compositions
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
IL132287A0 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2001068697A3 (en) Methods and compositions for immunoregulation
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
EP1028754A4 (en) PREVENTION OF IMMUNE REACTIVITY DUE TO DEPTH OR INHIBITION OF ANTIGENT PRESENTING CELLS
HU9600934D0 (en) Oligopeptides derived from c-reactive protein fragments
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
ATE316136T1 (de) Nierenpolycystose-gen
EP1023076A4 (en) USE OF THE P-TEN TUMOR SUPPRESSOR GENE IN THE DIAGNOSIS AND TREATMENT OF CANCER
EP1671646A3 (en) Methods of treating IgE-associated disorders and compositions for use therein
EP0891778A3 (en) Agents for the prevention and/or treatment of radiation-induced disorders
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
ZA988293B (en) Compositions and methods for the treatment of tumor.
PL335190A1 (en) Application of 9,10-seccocholesta-5,7,10(19)-thiene1,3-diole i.e. alphazazidole
WO2001062792A3 (en) Cancer treatment and prognosis involving hes-1 protein
MX9710304A (es) Composiciones para la preparacion de cuero.
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein
HU9401579D0 (en) Methods for administering biological agents and microparticle compositions

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF : [73] TRILLIUM THERAPEUTICS INC. - 96 SKYWAY AVENUE, - TORONTO, ONTARIO - M9W 4Y9 - CANADA - DATED 20.10.2006

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121106